Bolusing IV Administration Sets With Monoclonal Antibodies Reduces Cost and Chair Time: A Randomized Controlled Trial

Francesca Boyte; Brighid Scanlon; Robyn Matthews; Elise Button; Lee Jones; Therese Hayes; Grant Partridge; Michael Smith; Glen Andrew Kennedy; Melissa Eastgate; Nicole Clare Gavin

doi:10.1188/24.CJON.E9-E15

Bolusing IV Administration Sets With Monoclonal Antibodies Reduces Cost and Chair Time: A Randomized Controlled Trial

Francesca Boyte, Brighid Scanlon, Robyn Matthews, Elise Button, Lee Jones, Therese Hayes, Grant Partridge, Michael Smith, Glen Andrew Kennedy, Melissa Eastgate, Nicole Clare Gavin

Research output: Contribution to journal › Article › peer-review

Abstract

BACKGROUND: Monoclonal antibodies are widely used anticancer therapies. Increasing demand for ambulatory care necessitates exploration of effciency measures.

OBJECTIVES: The primary objective was to evaluate the impacts on chair time and associated cost of priming IV administration sets with a bolus of the prescribed monoclonal antibody drugs. A secondary objective was to assess the associated incidence of hypersensitivity reactions.

METHODS: A large tertiary hospital in Brisbane, Australia, conducted a randomized controlled trial (N = 128) with a two-arm design. Included monoclonal antibodies were daratumumab, obinutuzumab, pembrolizumab, and nivolumab.

FINDINGS: There was a statistically significant reduction in chair time for obinutuzumab, pembrolizumab, and nivolumab compared with the control. Findings suggest that this priming intervention reduces chair time and cost for some monoclonal antibody drugs. Future research could assess this practice in other oncology therapies.

Original language	English
Pages (from-to)	E9-E15
Number of pages	7
Journal	Clinical Journal of Oncology Nursing
Volume	28
Issue number	5
DOIs	https://doi.org/10.1188/24.CJON.E9-E15
Publication status	Published - Oct 2024
Externally published	Yes

Keywords

chair time
cost saving
IV administration
monoclonal antibodies
priming

Access to Document

10.1188/24.CJON.E9-E15Licence: In Copyright

Cite this

@article{c6423f82ebe14711b1edcd84c71480dd,

title = "Bolusing IV Administration Sets With Monoclonal Antibodies Reduces Cost and Chair Time: A Randomized Controlled Trial",

abstract = "BACKGROUND: Monoclonal antibodies are widely used anticancer therapies. Increasing demand for ambulatory care necessitates exploration of effciency measures. OBJECTIVES: The primary objective was to evaluate the impacts on chair time and associated cost of priming IV administration sets with a bolus of the prescribed monoclonal antibody drugs. A secondary objective was to assess the associated incidence of hypersensitivity reactions. METHODS: A large tertiary hospital in Brisbane, Australia, conducted a randomized controlled trial (N = 128) with a two-arm design. Included monoclonal antibodies were daratumumab, obinutuzumab, pembrolizumab, and nivolumab. FINDINGS: There was a statistically significant reduction in chair time for obinutuzumab, pembrolizumab, and nivolumab compared with the control. Findings suggest that this priming intervention reduces chair time and cost for some monoclonal antibody drugs. Future research could assess this practice in other oncology therapies.",

keywords = "chair time, cost saving, IV administration, monoclonal antibodies, priming",

author = "Francesca Boyte and Brighid Scanlon and Robyn Matthews and Elise Button and Lee Jones and Therese Hayes and Grant Partridge and Michael Smith and Kennedy, {Glen Andrew} and Melissa Eastgate and Gavin, {Nicole Clare}",

year = "2024",

month = oct,

doi = "10.1188/24.CJON.E9-E15",

language = "English",

volume = "28",

pages = "E9--E15",

journal = "Clinical Journal of Oncology Nursing",

issn = "1092-1095",

publisher = "Oncology Nursing Society",

number = "5",

}

TY - JOUR

T1 - Bolusing IV Administration Sets With Monoclonal Antibodies Reduces Cost and Chair Time

T2 - A Randomized Controlled Trial

AU - Boyte, Francesca

AU - Scanlon, Brighid

AU - Matthews, Robyn

AU - Button, Elise

AU - Jones, Lee

AU - Hayes, Therese

AU - Partridge, Grant

AU - Smith, Michael

AU - Kennedy, Glen Andrew

AU - Eastgate, Melissa

AU - Gavin, Nicole Clare

PY - 2024/10

Y1 - 2024/10

N2 - BACKGROUND: Monoclonal antibodies are widely used anticancer therapies. Increasing demand for ambulatory care necessitates exploration of effciency measures. OBJECTIVES: The primary objective was to evaluate the impacts on chair time and associated cost of priming IV administration sets with a bolus of the prescribed monoclonal antibody drugs. A secondary objective was to assess the associated incidence of hypersensitivity reactions. METHODS: A large tertiary hospital in Brisbane, Australia, conducted a randomized controlled trial (N = 128) with a two-arm design. Included monoclonal antibodies were daratumumab, obinutuzumab, pembrolizumab, and nivolumab. FINDINGS: There was a statistically significant reduction in chair time for obinutuzumab, pembrolizumab, and nivolumab compared with the control. Findings suggest that this priming intervention reduces chair time and cost for some monoclonal antibody drugs. Future research could assess this practice in other oncology therapies.

AB - BACKGROUND: Monoclonal antibodies are widely used anticancer therapies. Increasing demand for ambulatory care necessitates exploration of effciency measures. OBJECTIVES: The primary objective was to evaluate the impacts on chair time and associated cost of priming IV administration sets with a bolus of the prescribed monoclonal antibody drugs. A secondary objective was to assess the associated incidence of hypersensitivity reactions. METHODS: A large tertiary hospital in Brisbane, Australia, conducted a randomized controlled trial (N = 128) with a two-arm design. Included monoclonal antibodies were daratumumab, obinutuzumab, pembrolizumab, and nivolumab. FINDINGS: There was a statistically significant reduction in chair time for obinutuzumab, pembrolizumab, and nivolumab compared with the control. Findings suggest that this priming intervention reduces chair time and cost for some monoclonal antibody drugs. Future research could assess this practice in other oncology therapies.

KW - chair time

KW - cost saving

KW - IV administration

KW - monoclonal antibodies

KW - priming

UR - http://www.scopus.com/inward/record.url?scp=85204941874&partnerID=8YFLogxK

U2 - 10.1188/24.CJON.E9-E15

DO - 10.1188/24.CJON.E9-E15

M3 - Article

C2 - 39324709

AN - SCOPUS:85204941874

SN - 1092-1095

VL - 28

SP - E9-E15

JO - Clinical Journal of Oncology Nursing

JF - Clinical Journal of Oncology Nursing

IS - 5

ER -

Bolusing IV Administration Sets With Monoclonal Antibodies Reduces Cost and Chair Time: A Randomized Controlled Trial

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this